Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy

• Status: Completed
• Trial end date: 2018-05-01
• Target enrollment: 0
• Participant gender: All

Summary

We hypothesize that delayed graft function and ITBS events may be related to small blood clots (microthrombi) that collect in the kidneys and liver after cardiac death. Treatment of the DCD organs with a thrombolytic agent prior to implantation may reduce post-transplant morbidity and mortality, and may ultimately result in a greater number of transplantable livers and kidneys.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: The Cleveland Clinic
• Collaborator: Health Resources and Services Administration (HRSA)
• Treatments: Fibrinolytic Agents; Tissue Plasminogen Activator

Criteria

Inclusion Criteria:

• Adults aged 18 years and older

• Subjects willing/able to provide written consent

• Subjects willing/able to comply with study requirements

• Subjects who will receive a solitary organ transplant

Exclusion Criteria:

• Subjects requiring multi-organ transplants

• Women who are pregnant

• Subjects with current severe systemic infection

• Subjects with an active infection